Get Your Personalized Supplement StackSupplement Stack Quiz

Micronized Akg

Q: Is micronized vaginal progesterone safe?

Yes, it is generally safe when used as directed, and side effects are typically mild and transient. Monitoring by a healthcare provider is recommended.

Q: When should treatment be initiated?

Treatment should be started as prescribed by a healthcare provider, usually at the onset of a threatened miscarriage, and continued until 16 weeks.

Q: What results can I expect from this treatment?

You may see an increase in live birth rates, particularly if you have a history of recurrent miscarriages; however, the effect is modest yet clinically significant.

Q: Can it prevent miscarriage?

Micronized vaginal progesterone supports pregnancy but cannot guarantee against miscarriage; it is an adjunct treatment to improve chances of a successful outcome.

Also known as: Micronized progesterone, Micronized progesterone capsules, MP, Micronized progesterone vaginal insert, Micronized Progesterone

Overview

Micronized progesterone is a finely ground formulation of the hormone progesterone, a crucial steroid hormone involved in regulating the menstrual cycle and maintaining pregnancy. It is synthesized in the ovaries and placenta, playing vital roles in preparing the endometrium for implantation and supporting early pregnancy. Administered primarily via the vaginal or rectal route, micronized progesterone is designed to enhance absorption and minimize first-pass metabolism. Extensive research, including randomized controlled trials and systematic reviews, has established its efficacy, particularly among women facing threatened miscarriages or those with a history of recurrent pregnancy loss. It is recognized for improving live birth rates in these populations and is generally well-tolerated.

Benefits

Micronized vaginal progesterone significantly enhances live birth rates, particularly in women experiencing threatened miscarriages. The PRISM trial demonstrated a live birth rate of 75% in the progesterone group compared to 72% in the placebo group, showing a modest yet clinically relevant benefit. Another study revealed improved outcomes when treatment commenced during the luteal phase, with a live birth rate of 68% in the treatment group versus 51% in controls, especially beneficial for those with recurrent miscarriages. The most pronounced benefits are observed when treatment begins early in pregnancy during cases of threatened miscarriage.

How it works

Micronized progesterone acts by binding to progesterone receptors in the endometrium, enhancing uterine lining receptivity for embryo implantation. This process modulates gene expression and supports the necessary cellular functions for maintaining pregnancy. Through localized vaginal administration, it increases local progesterone concentrations, reducing systemic side effects while creating a favorable environment for embryo survival and lowering miscarriage risks.

Side effects

Micronized progesterone is largely well-tolerated. Common side effects occurring in over 5% of users may include mild vaginal discharge, itching, or irritation at the application site. Less common side effects (1-5%) might involve dizziness, headache, or nausea, but these are typically mild and rarely require treatment discontinuation. Serious side effects are very uncommon (<1%) and potentially include allergic reactions or significant vaginal irritation. While interactions with other hormonal medications can occur, they are generally not clinically significant in pregnancy support contexts. Caution is advised for individuals with a history of thromboembolic disorders, although the risks associated with vaginal administration are low.

Dosage

The recommended dosage of micronized progesterone for supporting pregnancy is typically 400 mg, administered vaginally or rectally twice daily. This dosage was utilized in the PRISM trial until 16 weeks of gestation. While no strict upper limit for vaginal administration exists, doses exceeding 400 mg twice daily should not be taken without medical supervision. It is advised to initiate treatment based upon healthcare provider recommendations, generally starting when cases of threatened miscarriage are identified and continuing until the 16th week of gestation for optimal benefits.

FAQs

Is micronized vaginal progesterone safe?

Yes, it is generally safe when used as directed, and side effects are typically mild and transient. Monitoring by a healthcare provider is recommended.

When should treatment be initiated?

Treatment should be started as prescribed by a healthcare provider, usually at the onset of a threatened miscarriage, and continued until 16 weeks.

What results can I expect from this treatment?

You may see an increase in live birth rates, particularly if you have a history of recurrent miscarriages; however, the effect is modest yet clinically significant.

Can it prevent miscarriage?

Micronized vaginal progesterone supports pregnancy but cannot guarantee against miscarriage; it is an adjunct treatment to improve chances of a successful outcome.

Research Sources

https://doi.org/10.1016/j.ajog.2016.09.096 – This study provides evidence on the efficacy of micronized vaginal progesterone in improving live birth rates in women with threatened miscarriages. The findings support the initiation of treatment during early pregnancy to optimize outcomes.
https://doi.org/10.1016/j.fertnstert.2019.02.022 – The meta-analysis evaluated the effects of micronized progesterone in various contexts of pregnancy support, confirming its role and benefits for women with recurrent pregnancy loss, particularly when treatment starts early.
https://doi.org/10.1016/j.ogrm.2018.05.003 – This systematic review highlights the importance of micronized progesterone usage in pregnancy, detailing its mechanisms and significant positive effects on live birth rates in at-risk populations.